- Home
- NXGL vs PRPH Comparison
NXGL vs PRPH Comparison
Compare NXGL & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | PRPH |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 4.1M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | NXGL | PRPH |
|---|---|---|
| Price | $1.55 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.4K | ★ 2.7M |
| Earning Date | 11-11-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,666,000.00 | $5,055,000.00 |
| Revenue This Year | $39.28 | $221.82 |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.37 | N/A |
| 52 Week Low | $1.45 | $0.50 |
| 52 Week High | $4.95 | $9.35 |
Technical Indicators
Market Signals| Indicator | NXGL | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 59.62 |
| Support Level | $1.55 | $0.08 |
| Resistance Level | $1.90 | $1.15 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 14.02 | 41.01 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.